Sarah Runswick
Allgemeine Gewerbeschule Basel(CH)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Advanced Breast Cancer Therapies, Synthesis and biological activity, Protein Degradation and Inhibitors, PARP inhibition in cancer therapy
Most-Cited Works
- → Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation(2017)3,123 cited
- → OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer(2019)736 cited
- → Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)(2010)261 cited
- → Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines(2012)257 cited
- → Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization(2017)151 cited
- → Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)(2012)83 cited
- → Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses(2024)38 cited
- → OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).(2017)37 cited
- → RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib(2013)34 cited
- → Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.(2018)12 cited